You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t

    SBC: AADI, LLC            Topic: 102

    DESCRIPTION provided by applicant In it is estimated that there will be new bladder cancer cases in the United States resulting in deaths Most cases present with nonmuscle invasive bladder cancer NMIBC Intravesical bacillus Calmette Guerin BCG which elicits a nonspecific local immune response is considered the standard first line treatment However ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Whole Brain Nanoscale Preservation Imaging

    SBC: Nectome Inc.            Topic: 101

    Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications

    SBC: ARIMA GENOMICS, INC.            Topic: 172

    DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a topical fixed-dose combination drug for peripheral neuropathic pain.

    SBC: WinSanTor, Inc.            Topic: NINDS

    PROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. The top two major causes of peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents. Currently, there are no FDA-approved treatments to prevent or reverse ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Engineering a unique antibody for patients with RA

    SBC: ABWIZ BIO INC            Topic: NIAID

    RA is one of the most common chronic autoimmune disorders that can lead to complete joint destruction and severe disability if untreated. There is no cure for RA and up to 50% of RA patients do not respond to anti-TNF therapies as circulating Th-17/IL-17 levels are highly elevated subsequent to TNF blockade. For this subset of RA patients, disruption of a novel pathway that impairs the synergy bet ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  8. A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Caregiver Application and AI-Enabled Intelligent Assistant to Support Families and Formal Care Providers in Caring for Persons with Alzheimer's Disease and Related Dementias

    SBC: Whiplash Technology, Inc.            Topic: NIA

    PROJECT ABSTRACT Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can address the specific care needs of each AD patient. To address this critical gap, we developed CareVirtue, an innovative web/mobile application for family ca ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Recombinant Fc fusions for treatment of uropathogenic E. coli

    SBC: Planet Biotechnology Incorporated            Topic: 300

    Urinary tract infections (UTIs) are among the most common bacterial infections, affecting 150 million people worldwide each year. In the USA, community-acquired UTIs account for about 11 million cases each year that cost the U.S. public health budget $5 billion annually. Uropathogenic Escherichia coli (UPEC) accounts for up to 80% of UTIs. While UTIs are currently treated with antibiotics, the fre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government